Group 1 - The core point of the article is that Wantai Biological's nine-valent HPV vaccine has received approval for market release in China, making it the first domestic company to achieve this milestone after Merck [1] - The vaccine is priced at 499 yuan per dose, which is approximately 40% of the price of imported nine-valent HPV vaccines, indicating a significant cost advantage for consumers [1] - The approval is expected to enhance the company's product portfolio, create new revenue and profit growth opportunities, and strengthen its market position [1] Group 2 - According to a study by the Chinese Center for Disease Control and Prevention, the HPV vaccine coverage rate among women aged 9-45 in China is only 27.43%, compared to about 67% in Western countries, suggesting substantial room for growth in the market [2] - The rapid development of domestic HPV vaccines is supported by national policies, including the "Cervical Cancer Elimination Action Plan (2023-2030)" which aims to promote HPV vaccination [2] - Wantai Biological has initiated clinical trials for the nine-valent HPV vaccine in males, and market forecasts suggest that the HPV vaccine market in China could reach 62.54 billion yuan by 2031 as awareness and vaccination rates improve [2]